ClinicalTrials.gg
RecruitingNCT06863194PRO-CKDUpdated May 16, 2025

Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial

A Phase 1/2 interventional study of Probiotic Supplementation (Lactobacillus plantarum) and Placebo Tablets in Kidney Disease, Chronic, Renal Insufficiency, Chronic and Gut Dysbiosis, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Mansoura University · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.

Planned enrollment
20th of 44
72 · median 64
Started
2025
with 16 others
Phase 1/2
2 of 64
2 open now
Primary completion
2025-10
later than 6 of 27 live
Registered
35th of 64
by date
Lead sponsor
6 of 64
Mansoura University

Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 20th largest by planned enrollment of the 44 interventional ones that give a count, is one of 17 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 6 of the 27 other live ones, and was the 35th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether probiotic supplementation can slow disease progression in patients with moderate to severe chronic kidney disease (CKD). The trial will also assess the safety of probiotics in these patients.

The main questions the study aims to answer are:

Does probiotic supplementation improve kidney function by reducing serum creatinine levels and protein in urine? Does it reduce inflammation and metabolic imbalances in CKD patients? Does it affect gut microbiota composition and lower harmful toxins in the body? Is probiotic supplementation safe and well-tolerated in CKD patients?

Participants will:

Be randomly assigned to receive either probiotics or a placebo for 6 months. Have clinic visits every 6 months for checkups, blood tests, and urine tests. Be monitored for any side effects and changes in kidney function. Researchers will compare the probiotic group to the placebo group to determine whether probiotics are effective in slowing CKD progression.

Read the detailed description

Background \& Rationale:

Chronic Kidney Disease (CKD) is associated with significant alterations in gut microbiota, leading to the production and accumulation of uremic toxins such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS). These toxins contribute to systemic inflammation, oxidative stress, and accelerated kidney disease progression, ultimately increasing cardiovascular mortality. The disruption of gut barrier function and dysbiosis are major contributing factors in CKD pathophysiology.

Probiotic supplementation has been proposed as an adjuvant therapy to modulate gut microbiota, enhance intestinal barrier integrity, and reduce systemic inflammation. Probiotics, particularly Lactobacillus species, have been shown to ferment dietary fiber, produce beneficial metabolites, and competitively inhibit harmful bacteria. Despite some promising findings, prior clinical trials have reported inconsistent results, necessitating further investigation into the efficacy of probiotics in slowing CKD progression.

This randomized, double-blind, placebo-controlled clinical trial aims to assess the impact of probiotic supplementation on renal function, systemic inflammation, and gut-derived uremic toxins in patients with moderate to severe CKD (Stages III-IV).

Study Design \& Methodology This trial is a parallel-group, double-blind, randomized controlled study with a 1:1 allocation ratio. Participants will be recruited from the Urology and Nephrology Center, Mansoura University, and randomized into either the probiotic intervention group or the placebo control group.

Intervention Details:

Study Group: Participants will receive probiotic supplementation (Lactogemikan; Pescado Pharmaceuticals, Egypt), containing 10 billion CFU of Lactobacillus plantarum per tablet. The dose will be one tablet daily for 6 months.

Control Group: Participants will receive an identical placebo tablet for 6 months.

Both groups will be followed up for an additional 6 months after treatment cessation to evaluate any persistent effects of probiotic supplementation.

Primary \& Secondary Outcomes:

The trial will measure:

Primary Outcomes:

Changes in serum creatinine, estimated glomerular filtration rate (eGFR), and urinary protein levels over 12 months.

Secondary Outcomes:

Changes in systemic inflammatory markers (C-reactive protein, ferritin, total cholesterol, albumin).

Alterations in gut microbiota composition, assessed by urinary indican (indoxyl sulfate) levels before and after treatment.

Evaluation of safety and tolerability of probiotic supplementation in CKD patients.

Randomization \& Blinding:

Randomization: Conducted via a computerized random sequence generator.

Blinding:

Double-blinded (both participants and investigators are blinded to group assignments).

The probiotic and placebo tablets are identical in appearance, taste, and packaging.

Follow-Up \& Monitoring:

Participants will be evaluated at three time points:

Baseline assessment (before treatment initiation) 6-month follow-up (after completing treatment) 12-month follow-up (6 months post-treatment cessation) At each visit, clinical, biochemical, and microbiota assessments will be conducted. Any adverse events will be documented.

Statistical Analysis Plan Data will be analyzed using R statistical software (R Core Team, 2023).

Descriptive statistics will summarize baseline characteristics. Continuous variables will be assessed using the Shapiro-Wilk test for normality.

Depending on normality:

Welch's t-test (normally distributed variables) Mann-Whitney U test (non-normally distributed variables) Categorical variables will be analyzed using the Chi-square test. A p-value \< 0.05 will be considered statistically significant. Ethical Considerations \& Regulatory Compliance Ethical Approval: The study has been approved by the Institutional Review Board (IRB) of Mansoura Faculty of Medicine, Mansoura University (IRB Code: MD.24.06.864).

Informed Consent: All participants will provide written informed consent before enrollment.

Adverse Events Reporting: Any serious adverse events (SAEs) will be immediately reported to the IRB and Ethics Committee.

Confidentiality: Participant data will be anonymized and stored securely. Significance of the Study This study aims to provide new insights into the therapeutic role of probiotics in CKD patients. If effective, probiotic supplementation may offer a low-cost, non-invasive adjunct therapy to slow kidney disease progression, reduce inflammation, and improve metabolic health.

By investigating the mechanistic role of probiotics in modulating gut-derived toxins, this trial may contribute to developing novel microbiome-targeted interventions in nephrology practice.

03

Conditions studied

  • Kidney Disease, Chronic
  • Renal Insufficiency, Chronic
  • Gut Dysbiosis
  • Uremic Toxins

Keywords

  • Chronic Kidney Disease (CKD)
  • Probiotics
  • Gut Microbiota
  • Uremic Toxins
  • Indoxyl Sulfate (IS)
  • Inflammation in CKD
  • Dysbiosis in CKD
  • Lactobacillus plantarum
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥ 18 years (both males and females).
  • Diagnosed with Chronic Kidney Disease (CKD) Stage III or IV, confirmed by .
  • Stable medical condition with no recent hospitalization for acute kidney injury or other serious illnesses.
  • Not currently on probiotic supplementation or prebiotic therapy.
  • Willing to provide and comply with the study protocol, including clinic visits and sample collection.

Exclusion criteria

Exclusion Criteria:

  • CKD Stage I, II, or V, or on dialysis.
  • Currently using probiotics or prebiotics as part of their diet or treatment.
  • History of active (cancer) or undergoing chemotherapy.
  • Significant gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome, or recent GI surgery).
  • Pregnant or breastfeeding women (due to safety concerns).
  • Patients with diseases (e.g., lupus, rheumatoid arthritis).
  • Individuals on long-term antibiotic or anti-inflammatory medication that could interfere with microbiota composition.
  • Individuals with severe behavioral or cognitive disorders that may prevent adherence to the study protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Arm 1 (Intervention Group) Arm Title: Probiotic Supplementation Group Description: Participants in t

    Participants in this group will receive Lactogemikan (Probiotic Supplement), which contains 10 billion CFU of Lactobacillus plantarum per tablet. They will take one tablet daily for 6 months. The purpose of this intervention is to evaluate whether probiotic supplementation can slow the progression of chronic kidney disease (CKD) by modulating gut microbiota, reducing systemic inflammation, and decreasing uremic toxin levels. Participants will be monitored through clinical visits and laboratory tests at baseline, and 6 months to assess kidney function (eGFR, serum creatinine, urinary protein levels), inflammatory markers (CRP, ferritin, albumin), and gut microbiota composition (urinary indican levels).

    Drug: Probiotic Supplementation (Lactobacillus plantarum)

  • Placebo comparator
    Arm 2 (Control Group) Arm Title: Placebo Group Description: Participants in this group will receive

    Participants in this group will receive a placebo tablet that is identical in appearance, taste, and packaging to the probiotic supplement but contains no active probiotic ingredients. They will take one tablet daily for 6 months. This group serves as a control to compare the effects of probiotic supplementation against a non-active intervention. Participants will undergo the same clinical visits and laboratory assessments as the intervention group at baseline, and 6 months. Outcomes assessed will include kidney function (eGFR, serum creatinine, urinary protein levels), systemic inflammation markers (CRP, ferritin, albumin), and gut microbiota composition (urinary indican levels) to determine whether the probiotic has a measurable impact compared to the placebo.

Interventions

  • DrugLactobacillus plantarumStudies of Lactobacillus plantarumLactobacillus plantarum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in this group will receive Lactogemikan (Probiotic Supplement), which contains 10 billion CFU of Lactobacillus plantarum per tablet. The dose is one tablet daily for 6 months. This probiotic is intended to modulate gut microbiota, reduce systemic inflammation, and decrease uremic toxins (indoxyl sulfate) in CKD patients. The intervention will be compared to a placebo to evaluate its effectiveness in slowing CKD progression and improving metabolic and inflammatory markers.

  • DrugPlacebo Tablets

    Participants in this group will receive an inert placebo tablet that is identical in appearance, taste, and packaging to the probiotic supplement but contains no active probiotic ingredients. The dose is one tablet daily for 6 months. The placebo serves as a control to compare the effects of the probiotic intervention. Both groups will undergo identical monitoring and follow-up assessments to determine whether the probiotic has a significant effect on kidney function, inflammation, and gut microbiota composition.

06

What researchers measure

Primary outcomes

  1. Change in Estimated Glomerular Filtration Rate (eGFR)

    eGFR will be calculated using the CKD-EPI 2021 equation to assess changes in kidney function over time. A slower decline in eGFR in the probiotic group compared to the placebo group would indicate a beneficial effect.

    Time frame: Baseline, and 6 months

Secondary outcomes

  1. Change in Gut-Derived Uremic Toxins (Indoxyl Sulfate)

    Urinary indican (indoxyl sulfate) levels will be measured to assess whether probiotics alter gut microbiota composition and reduce uremic toxin production.

    Time frame: Baseline, and 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G1060-9. doi: 10.1152/ajpgi.00202.2007. Epub 2008 Feb 21. PubMed 18292183 ↗
  • de Araujo EMR, Meneses GC, Carioca AAF, Martins AMC, Daher EF, Silva Junior GB. Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial. J Bras Nefrol. 2023 Apr-Jun;45(2):152-161. doi: 10.1590/2175-8239-JBN-2022-0021en. PubMed 36112723 ↗
  • Miranda Alatriste PV, Urbina Arronte R, Gomez Espinosa CO, Espinosa Cuevas Mde L. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp. 2014 Mar 1;29(3):582-90. doi: 10.3305/nh.2014.29.3.7179. PubMed 24559003 ↗
  • Tian N, Li L, Ng JK, Li PK. The Potential Benefits and Controversies of Probiotics Use in Patients at Different Stages of Chronic Kidney Disease. Nutrients. 2022 Sep 29;14(19):4044. doi: 10.3390/nu14194044. PubMed 36235699 ↗

Individual participant data

Plan to share: No — Due to patient confidentiality and ethical considerations, individual participant data (IPD) will not be shared.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2025, 6 months after the start.

Of 22 phase 1/2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 7, 2025
StartActual
Apr 3, 2025
Primary completionEst.
Oct 3, 2025
CompletionEst.
Oct 20, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06863194
Responsible party
Samar Elshahat Saleh (Principal Investigator, Mansoura University) — Principal investigator
First posted
Mar 7, 2025
Start date
Apr 3, 2025
Primary completion
Oct 3, 2025 (estimated)
Completion
Oct 20, 2025 (estimated)
Last update
May 16, 2025

Study contacts

Samar Elshahat Saleh
Contact
samarelshahat@mans.edu.eg
00201023771331

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactobacillus plantarum

Start the discussion